gmail.com.2Department of Neuroscience, Biomedicine and Movement Science, University of Verona, Verona, Italy.3Division of Neurology, « Franz Tappeiner » Hospital, Merano, BZ, Italy.4Department of Neurology, Christian Doppler Klinik, Paracelsus Medical University, Salzburg, Austria.5Center for Cognitive Neuroscience, Salzburg, Austria.6Public Health, Health Services Research and HTA, University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria.7Health Agency of Tuscany, Florence, Italy.8Department of Experimental and Clinical Medicine, Neurological Clinic, Marche Polytechnic University, Via Conca 71, 60020, Ancona, Italy.9Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.AbstractBACKGROUND:
Approximately one-third of patients with epilepsy presents seizures despite adequate treatment. Hence, there is the need to search for new therapeutic options. Cannabidiol (CBD) is a major chemical component of the resin of Cannabis sativa plant, most commonly known as marijuana. The anti-seizure properties of CBD do not relate to the direct action on cannabinoid receptors, but are mediated by a multitude of mechanisms that include the agonist and antagonist effects on ionic channels, neurotransmitter transporters, and multiple 7-transmembrane receptors. In contrast to tetra-hydrocannabinol, CBD lacks psychoactive properties, does not produce euphoric or intrusive side effects, and is largely devoid of abuse liability.
The aim of the study was to estimate the efficacy and safety of CBD as adjunctive treatment in patients with epilepsy using meta-analytical techniques.
Randomized, placebo-controlled, single- or double-blinded add-on trials of oral CBD in patients with uncontrolled epilepsy were identified. Main outcomes included the percentage change and the proportion of patients with
View the Original article